THE FUTURE OF CLINICAL TRIALS WEBINAR
Now more than ever, the clinical trials sector is capable of advancing medicine and contributing to a positive future for the human race. Multiple forces are elevating and amplifying the importance of clinical trials around the world. The cost and value of medicine are becoming increasingly critical as the global life sciences industry seeks to innovate high-quality drugs faster and cheaper.
There is now a vast array of data at our fingertips, enough to enable truly personalized medicine on a previously unachievable scale. In turn, this is facilitating new cell and gene therapies that target smaller population groups. And all these changes are empowering patients who, for decades, have been asking for a voice and for greater autonomy in the development of their own treatments.
In this new era of clinical trials, compliance continues to be an overarching imperative along with the need for sustainability. More and more clinical trials are leveraging virtual health tools and mobile technology, and robust yet agile logistics solutions and supply chain processes are now essential to the success of each trial.
Since January 2019 Thomas Ellmann has been responsible for the X-BU development of Clinical Trials Logistics. He coordinates the Solutions and Services development across the different Divisions in DP DHL and serves as a member of the Global Life Sciences Senior Management Sector Team.
In past months he supported DHL Covid-19 Vaccines distribution as a co-author of the White Papers on “Pandemic Resilience” and is leading the business development efforts in the Global Task Force to support distribution readiness for global vaccines manufacturers and Governments and NGOs.
Markus Ofenlock is Head Global Clinical Distribution at Roche. Based in Basel, Switzerland, Markus’ career within the organization has included not only clinical distribution but also supply chain management.
Rebeca believes that patients must be at the center of clinical trials. For years, she has provided solutions with decentralized elements to sponsors and CROs. As Director of emovis Homecare Visits, she and her team have supported over 50 clinical trials with homecare visits, getting to see its benefits but also understanding the challenges some elements can bring for different stakeholders.
Currently, she is working on combining the benefits of digital innovation with emovis' expertise and experience to bring trials even closer to patients and provide decentralized clinical trial solutions.
Peter Turner is Head of Supply Logistics, Comparators and Collaborations at GSK. Coming from a scientific background and the UK’s prestigious University of Oxford, Peter’s career with GSK spans more than 16 years and includes extensive experience in global supply chain planning.
Dr. Matthias Roos works as Pharma Sector Lead at Climedo where he focuses on corporate strategies around patient centricity and knowledge building. He previously gained experience in managing clinical trials in the pharma sector and as a management consultant at McKinsey & Company.
Matthias has worked as a Postdoc at MIT in the field of protein science and holds a PhD in Physics. In 2017, he won the Ernst Award of the German Chemical Society and became a research fellow of the German National Academy of Sciences Leopoldina. So far, he has published 15 peer-reviewed publications in scientific journals.
Global Clinical Trial enthusiast, strategic leader, and pragmatic problem solver, who understands the value of creativity and teamwork to achieve compliance, manage risks and deliver timely results to contribute to company’s growth and development. 17 yrs experience on both Sponsor and CMO side. Currently hold a position of Associate Director, Network Strategy, Clinical Supply Logistics at BMS working in Global Clinical Supply Chain division.
In the current role, support the development, implementation, and maintenance of an integrated global Clinical Supply Logistics Network to meet the evolving needs of BMS investigational programs & clinical geographic footprint, in alignment with BMS business priorities, company structures and operating models, as well as international regulatory requirements. Contribute to CSL strategy development, sponsor development and implementation of assigned CSL strategic priorities and multi-year network integration programs. Love all the opportunities for development and evolution supply chain presents you with on any given day.